Sensus Healthcare, Inc.

Good day and welcome to the Census Healthcare Second Quarter 2024 Financial Results Conference Call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero on your telephone keypad. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star then 1 on your telephone keypad. To withdraw your question, please press star then 2. Please note this event is being recorded. I would now like to turn the conference over to Kim Golodetz for opening remarks. Please go ahead.

Thank you. This is Kim Golodetz with LHA. Thank you all for participating in today's call. Joining me from Census Healthcare are Joe Sardano, Chairman and Chief Executive Officer, Michael Sardano, President and General Counsel, and Javier Rampolla, Chief Financial Officer. As a reminder, some of the matters that will be discussed during today's call contain forward-looking statements within the meaning of federal securities laws. All statements other than historical facts that address the Census Healthcare assumes, plans, expects, believes, intends or anticipates, and other similar expressions, will, should, or may occur in the future, are forward-looking statements. The forward-looking statements are management's beliefs based on currently available information as of the date of this conference call, August 8th, 2024. Census healthcare undertakes no obligation to revise or update any forward-looking statements except as required by law. All forward-looking statements are subject to risks and uncertainties as described in the company's Forms 10-K and 10-Q. During today's call, references will be made to certain non-GAAP financial measures. Census believes these measures provide useful information for investors, yet they should not be considered as a substitute for GAAP, nor should they be viewed as a substitute for operating results determined in accordance with GAAP. A reconciliation of non-GAAP to GAAP results is included in today's financial results press release. With that said, I'd like to turn the call over to Joe Sardano. Joe?

Thank you, Kim, and good afternoon, everyone. Our sales momentum continued in the second quarter of 2024 with very strong year-over-year revenue growth, along with positive net income and positive adjusted EBITDA. We continue to drive sales as our customers appear to have adjusted to the current macroeconomic environment. We shipped 23 systems during the quarter with three going international markets. This compares with 13 systems shipped in the year ago a quarter. We were pleased that many of the shipments were for our SRT vision systems with image-guided SRT with a higher number of such systems sold to a very large customer. We appreciate the dedication of this customer in choosing a far more patient-friendly and equally efficacious option versus Mohs surgery. Our fair deal agreement, which reflects our new recurring revenue model, is off to a fantastic start. We launched this option in March at the American Academy of Dermatology annual meeting, and it augments our leasing programs as well as outright sales. As I speak with you today, we have 15 signed contracts under this program, and I wouldn't be surprised if the total number reaches up to 50 by the end of the year based on our current activity levels. Our fair deal agreement addresses customer needs to deploy capital to other areas of their businesses, especially under challenging macroeconomic conditions. Given the growing utilization of SRT to treat non-melanoma skin cancer and keloids, and the interest we've generated to date, we expect this option to contribute to our growth for years to come. All these agreements will begin to provide recurring revenues to Census beginning in 2025 with significant volumes projected for the second half. During the second quarter, I was honored to be asked to join the Industry Advisory Council of the American Society of Dermatologic Surgery. In that role, I participated in a small but select seminar with important KOLs. at the event there was keen interest in our fair deal program and we generated a number of leads. That response, along with the signed agreements to date, underscores my optimism about our prospects. Turning now to transdermal infusion, or TDI, recall that we filed our 510 application with the US FDA in the fourth quarter of 2023. The response times have been impacted from the agency due to overwhelming number of submissions by the healthcare industry since COVID. Our engineers have continued to develop this product with feedback from our KOLs and the many pharma companies interested in this technology. As a result, we've decided to add these many new features, which were considered to be phase two development to the current product. Therefore, we will resubmit our application with a more robust, features-rich technology. We feel that we will submit this application in Q3, which is pretty much past the bottleneck period at the FDA. With those remarks, I'll turn the call over to Michael Sardano for a brief update on our international business. Michael.